Introduction
============

Esophageal carcinoma is one of the most common malignancies and occupies the sixth leading cause of cancer-related death in the world [@B1]. About 49% of all new cases occurred in China [@B2]. Although neo-adjuvant chemoradiotherapy is recommended in resectable locally advanced esophageal carcinoma, what we have to be confronted with is that the initial treatment for majority of these patients trends to be surgery in China for various reasons. The effectiveness of surgery alone has been unsatisfactory, since the high relapse rate reaches up to 43.3%-50.0% [@B3]-[@B5]. Local-regional recurrence and distant metastasis remain to be the main causes of death after surgery. Therefore, postoperative multidisciplinary treatment including chemotherapy (CT) and radiotherapy (RT) has been vigorously implemented. Theoretically, postoperative concurrent chemoradiotherapy (post-CCRT) should be beneficial in improving the local-regional control as well as reducing the distant metastatic rate. But the results of the available clinical trials have not been consistent with each other. This meta-analysis aims to determine whether CCRT improves survival and decreases recurrence rates compared with non-CCRT strategies for patients who have underwent esophagectomy and lymphadenectomy.

Materials and Methods
=====================

Search strategy
---------------

We systematically performed a literature search of the following databases: PubMed, PMC, EMBASE, Cochrane Central Register of Controlled Trials, Wanfang and Chinese National Knowledge Infrastructure (CNKI). All trials published by July 15, 2017 were targeted. Computer retrieval was performed using the following retrieval language: ("thoracic esophageal cancer" OR "thoracic esophageal carcinoma") AND ("postoperative" OR "adjuvant") AND ("concurrent chemoradiotherapy" OR "concomitant chemoradiotherapy"). To ensure that no studies were missed, manual searches of reference lists were also performed.

Inclusion and exclusion criteria
--------------------------------

Studies included in our analysis had to meet the following criteria: 1. clinical trials must compare post-CCRT with at least one of the following non-CCRT strategies: observation, postoperative CT (post-CT), postoperative RT (post-RT) or postoperative sequential chemoradiotherapy (post-SCRT) in the treatment of esophageal carcinoma after surgery; 2. data on survival, recurrence or toxicities had to be reported; 3. the language of publication was limited to English and Chinese with English abstract. All the randomized controlled trials (RCTs) and non-randomized controlled trials (NRCTs) were eligible. Articles for which the full text was not available were excluded.

Methodological quality assessment
---------------------------------

The quality of RCTs was assessed using the Jadad scale, the scores of which range from 0 to 5, with higher scores indicating better reporting [@B6]. However, since blinding of patients and clinicians to interventions was not evaluated because it was considered impossible in these kinds of study, the highest score in our assessment should be 3 which was similar to one previous meta-analysis [@B7]. NRCTs was evaluated according to the MINORS in which the global ideal score is 24 for non-randomized comparative studies [@B8].

Data extraction
---------------

For each study the following data were extracted: first author, year of publication, the author\'s country, the tumor staging and histology, the treatment regimens, number of patients who received any regimen; the outcomes including 1-year survival, 3-year survival, 5-year survival, the local-regional recurrence rate, distant metastasis rate and incidence of toxicities. Data extraction was performed independently by two researchers.

Statistical analyses
--------------------

Meta-analysis was performed with the software of Review Manager Version 5.3 and STATA version 12. The statistical heterogeneity of each study was assessed by I^2^ statistic with planned cut-off for significance of I^2^ =50% [@B9]. If I^2^≤50% which indicated no significant heterogeneity existing between the included studies, a fixed-effects model was adopted; otherwise, a random-effects model was employed and sensitivity analysis was further carried out using the leave one-out approach if there were more than two studies. Pooled analysis was performed using the Mantel-Haenszel model and reported as odds ratio (OR) with 95% confidence intervals (CI). The statistical significance of the pooled OR was determined by the Z-test. In the analysis of overall survival, an OR greater than 1 indicated a higher survival rate in patients who received post-CCRT and the point estimate of the OR was considered significant at the P\<0.05 level if the 95% CI did not include 1; while, in the analysis of recurrence or toxicities, an OR greater than 1 represented higher recurrence rate or risk of toxicities in patients who received post-CCRT and the point estimate of the OR was considered significant at the P\<0.05 level if the 95% CI did not include 1.

The Begg\'s and Egger\'s test in STATA were used to assess the potential publication bias. P\<0.05 was considered statistically significant and indicated possible publication bias. Further verification was carried out with the trim and fill method which was based on a formalization of the qualitative approach using the funnel plot [@B10]. The asymmetric part of the funnel plot was trimmed off and the true center of the funnel was estimated using the symmetric remainder, then the trimmed studies and their missing counterparts were replaced to produce a symmetrical funnel plot. The final estimates of the true mean and its variance were calculated based on the filled funnel plot. If the imputed values weren\'t markedly different from the original ones, it demonstrated that the publication bias had little effect on the pooled results indicating the strong reliability of the conclusion. While, when the values changed obviously after the trim and fill algorithm, we could not come to a safe conclusion because of the significant effect of the publication bias.

Results
=======

Study characteristics
---------------------

Overview of literature selection was showed in Figure [1](#F1){ref-type="fig"}. The characteristics details of all eligible studies were presented in Table [1](#T1){ref-type="table"}. Thirteen studies published in 14 articles[@B11]-[@B24] were eligible since one of the included studies had reported the 3-year and 5-year outcomes respectively in two articles[@B13], [@B14]. The 13 studies consisted of three RCTs [@B12], [@B19], [@B23], one prospective non-randomized controlled study [@B18], one prospective historical controlled study [@B22] and eight retrospective control studies[@B11], [@B13]-[@B17], [@B20], [@B21], [@B24]. The total number of patients identified in these 13 trials was 2165, including 998 patients treated with post-CCRT and the remaining 1167 with non-CCRT treatment after surgery. Ten studies enrolled patients with squamous cell carcinoma (SCC) only[@B12]-[@B19], [@B22]-[@B24], while for the other three studies both SCC and adenocarcinoma (AC) were eligible [@B11], [@B20], [@B21]. The type of SCC comprised 94.6% of all cases and AC accounted for 5.4%. Tumor stage of the patients ranged from phase Ⅱ to phase Ⅳ. Eleven out of 13 studies were conducted in Asian countries, including eight in China, three in Japan. The remaining two studies were one in Canada and one in America.

Assessment of the studies\' quality
-----------------------------------

The average Jadad score based on only three evaluation items (description of randomization, the right method of randomization and the dropouts and withdrawals) was 2.3 of 3 (Supplementary Table [S1](#SM0){ref-type="supplementary-material"}). The assessment details of the ten NRCTs was shown in Supplementary Table [S2](#SM0){ref-type="supplementary-material"}. The MINORS scores of all included NRCTs ranged between 16 and 22 with an average score of 18.2. Therefore, the overall methodological quality of included studies was relatively high.

Effects of post-CCRT on survival
--------------------------------

Figure [2](#F2){ref-type="fig"} showed the effect of post-CCRT on the survival rate compared with the non-CCRT treatment after surgery. There was statistically significant benefit on overall survival in the post-CCRT group. No significant heterogeneity was detected among the included studies, so fixed effects-model was adopted for analysis. The values of OR for CCRT comparing with non-CCRT were 1.66 (95% CI=1.30-2.11, P\<0.0001; Figure [2](#F2){ref-type="fig"}A) for 1-year survival, 1.50 (95% CI=1.24-1.81, P\<0.0001; Figure [2](#F2){ref-type="fig"}B) for 3-year survival, and 1.54 (95% CI=1.22-1.94, P=0.0003; Figure [2](#F2){ref-type="fig"}C) for 5-year survival. There was no publication bias for the pooled estimates of 1-year and 3-year survival. Publication bias was detected in the 5-year survival result since the P values for the Begg\'s and Egger\'s test were both less than 0.05. However, after the trim and fill algorithm had been performed, the pooled analysis incorporating the hypothetical studies continued to show a statistically significant survival benefit of post-CCRT (OR=1.313, 95% CI=1.047-1.646, P=0.018).

The survival benefits were also observed in the comparisons of post-CCRT with surgery alone (SA) or with post-RT. As shown in Figure [3](#F3){ref-type="fig"}, the values of OR for post-CCRT comparing with SA were 1.78 (95% CI=1.38-2.29, P\<0.00001; Figure [3](#F3){ref-type="fig"}A) for 1-year survival, 1.48 (95% CI=1.17-1.87, P=0.0009; Figure [3](#F3){ref-type="fig"}B) for 3-year survival, and 1.66 (95% CI=1.21-2.29, P=0.002; Figure [3](#F3){ref-type="fig"}C) for 5-year survival. Figure [4](#F4){ref-type="fig"} demonstrated that the OR of 5-year survival for post-CCRT comparing with post-RT was 1.67 (95% CI=1.10-2.53, P=0.02; Figure [4](#F4){ref-type="fig"}). Because there were no study reporting the 1-year survival and only two studies reporting the 3-year survival in the treatment of post-CCRT versus post-RT, we didn\'t do pooled analysis of them; since no study compared post-CCRT versus post-SCRT, we could not perform the pooled analysis either. Only one study compared post-CCRT with post-CT which showed non-significant survival benefit of post-CCRT probably because the patients number was too small [@B23].

Two studies performed respectively by Bédard et al. [@B11] and Liu et al. [@B18] added consolidation CT in the CCRT group but not in the control group. In order to rule out the impact of consolidation CT, further analysis was carried out which excluded these two studies. The analysis showed that comparing post-CCRT group with postoperative non-CCRT one, the OR values were 1.61 (95% CI=1.26-2.07, P=0.0002) for 1-year survival, 1.38 (95% CI=1.13-1.68, P=0.002) for 3-year survival, and 1.41 (95% CI=1.11-1.78, P=0.004) for 5-year survival (Table [2](#T2){ref-type="table"}).

When we focused on the studies which only included patients with SCC, OR values for post-CCRT group versus postoperative non-CCRT group were 1.63 (95% CI=1.26-2.11, P=0.0002) for 1-year survival, 1.44 (95% CI=1.18-1.74, P=0.0003) for 3-year survival, and 1.40 (95% CI=1.10-1.78, P=0.006) for 5-year survival (Table [3](#T3){ref-type="table"}). No publication bias was detected for the pooled estimates of 3-year and 5-year survival. And further trim and fill analysis certified that the publication bias in the analysis of 1-year survival had little influence on the pooled estimates (imputed OR=1.666, 95% CI=1.282-2.165, P=0.000).

Effects of post-CCRT on recurrence
----------------------------------

The detailed information about recurrence was available in eleven studies. Local-regional recurrence rate was significantly lower in the CCRT group compared with non-CCRT group (OR=0.58, 95% CI=0.46-0.72, P\<0.00001; Figure [5](#F5){ref-type="fig"}A). Since there was heterogeneity regarding the distant metastasis among the eleven studies (I^2^=60%), a random-effects model of analysis was used. There was no significant difference in the comparison of distant metastasis rate between the two groups (OR=0.94, 95% CI=0.68-1.30 P=0.70; Figure [5](#F5){ref-type="fig"}B). Sensitivity analysis was further performed with each study removed in turn. The pooled estimates of distant metastasis remained non-significant after each study was removed except the removal of Hsu 2014 which changed it to significant, indicating this study might influenced the pooled estimate. No publication biases for the estimates of recurrences were detected.

Toxicity of post-CCRT
---------------------

In the group of post-CCRT, the most common treatment-related mild toxicities (grade 1-2) were hypohemoglobinemia (25.7%-94.7%), leucocytopenia (33.3%-76.2%), thrombocytopenia (0-13.3%), nausea/vomiting (19.5%-86.7%), esophagitis (37.2%-66.7%) and stomatitis (17.1%-22.7%). The most prevalent severe complications (grade 3-4) were leucocytopenia (0-36.8%), hypohemoglobinemia (0-16.7%), thrombocytopenia (0-10.5%), nausea/vomiting (0-18.4%), and stomatitis (0-5.3%). Almost no studies reported grade 3 or worse late toxicities except for one in which 6.7% patients developed grade 3 lung toxicity, and 1 patient (0.6%) suffered grade 5 lung toxicity [@B14]. Toxicity comparison results were available in three studies which compared post-CCRT with post-CT or post-RT [@B13], [@B18], [@B23]. The pooled analysis results revealed that post-CCRT didn\'t increase the risk of grade 3-4 anemia (OR=1.26, 95% CI=0.34-4.73, P=0.73) and thrombocytopenia (OR=0.84, 95% CI=0.25-2.82, P=0.77) compared with post-CT or post-RT. Compared with post-RT, post-CCRT increased the risk of esophagitis (OR=1.71, 95% CI=1.09-2.66, P=0.02) but not pneumonitis (OR=0.89, 95% CI=0.55-1.44, P=0.63) or anastomotic stenosis (OR=0.54, 95% CI=0.18-1.59, P=0.26)(Supplementary Table [S3](#SM0){ref-type="supplementary-material"}). On the whole, with supportive care and symptomatic treatment, most of the patients could tolerate toxic reactions caused by post-CCRT.

Discussion
==========

Esophageal carcinoma is an aggressive malignancy with a poor prognosis. In East Asia, the majority of patients are esophageal SCC and receive surgery as the initial treatment, especially in China. But the most optimal postoperative treatment remains unclear. The only one previously published meta-analysis conducted by Zheng [@B25] indicated that patients with esophageal cancer after surgery could gain survival benefit from post-CCRT. But this meta-analysis with relatively small sample sizes only included two RCTs plus five NRCTs with a total of 523 patients. What\'s more, the methodological quality of all included studies hadn\'t been assessed in detail. Comparatively speaking, one more RCT and five more NRCTs up to July 15, 2017 were added in our meta-analysis, and the methodological quality was assessed to make sure that all studies included were of relatively high quality. This guaranteed the result\'s reliability of our study. Our meta-analysis based on the 2165 esophageal cancer patients confirmed that post-CCRT can significantly improve the overall survival as well as the local-regional control as compared with non-CCRT strategies after surgery. What\'s more, subgroup analyses showed that patients receiving post-CCRT had greater survival benefits than those treated with post-RT or SA. Because there was only one study comparing post-CCRT with post-CT and no study comparing post-CCRT with post-SCRT, we could not do pooled analysis about these groups. Taken together, the efficacy superiority of post-CCRT indicated that radiotherapy and concurrent chemotherapy could achieve good synergistic effect, which was also confirmed in the preoperative CCRT [@B26]-[@B28] and definitive CCRT [@B29], [@B30] for patients with esophageal carcinoma. There were two studies involving consolidation CT in the CCRT group but not in the control group. In order to rule out the impact of consolidation CT, further analysis was performed which excluded these two studies and the result still favored CCRT group in the comparison of long-term survival. This further confirmed the value of post-CCRT. In our study, post-CCRT significantly improved local-regional control but had no significant influence on the distant metastasis indicating that the survival improvement was mainly attributed to the better local-regional control in the CCRT group. This was in accordance with the preoperative CCRT and definitive CCRT in the treatment of esophageal carcinoma. What\'s more, meta-analysis of head and neck cancer also confirmed that post-CCRT significantly improved survival and local-regional control but not the distant control [@B31].

This meta-analysis is highly representative for including all the studies concerning about post-CCRT in the treatment of esophageal carcinoma all over the world. However, of the 13 studies included in this meta-analysis 8 were conducted in China and 3 in Japan. Therefore, our meta-analysis is of greater value in the guidance of treatment for esophageal cancer patients after surgery in East Asia, especially in China. SCC is the predominant histopathological type of esophageal cancer in East Asia, which is different from that of western countries. Since there are differences of pathogenetic mechanism and pathobiological behavior between AC and SCC, the optimized treatment modality may also be different. In our study, with SCC accounting for approximately 95% of all cases, subgroup analysis was performed with trials only including patients with SCC and the pooled result confirmed that post-CCRT could significantly improve the prognosis for these patients. Subgroup analysis with AC was not carried out for the lack of eligible study which enrolled patients with AC exclusively.

In order to improve therapeutic efficacy in the treatment of operable esophageal carcinoma, chemoradiotherapy is generally combined with surgery either preoperatively or postoperatively, especially for the locally advanced disease. Therefore, adverse effects of chemoradiotherapy and the tolerance of the patients should be of great concern, particularly for those who suffered from malnutrition caused by esophagus disease and the further strike of the surgery. CCRT could significantly improve the treatment efficacy, but frequently at the expense of increased toxicity. Actually, studies included in our meta-analysis showed that common toxicities related to post-CCRT were hypohemoglobinemia, leucocytopenia, thrombocytopenia, nausea/vomiting, esophagitis and stomatitis. Most of them were mild graded 1-2. Post-CCRT didn\'t significantly increase the risk of pneumonitis, anastomotic stenosis and severe hematologic toxicity compared with post-CT or post-RT. Though esophagitis was significantly increased in the CCRT group, it all graded no more than 2 and could be well tolerated after symptomatic and supportive treatment. What\'s more, meta-analyses studying about preoperative CCRT in the treatment of resectable esophageal carcinoma confirmed that CCRT was associated with no increased risk of postoperative morbidity or perioperative mortality [@B7], [@B32]. To sum up, it was safe, feasible and effective for the application of CCRT both in the preoperative and postoperative treatment for esophagus cancer patients.

Although our meta-analysis confirmed significant improvement in both loco-regional control and overall survival with post-CCRT in the treatment of esophageal carcinoma, there are still some issues need further clarification. First of all, we didn\'t mention how to identify and select the appropriate population most likely to benefit from post-CCRT. Large-scale retrospective studies and prospective trials are warranted in order to find out optimal target population. Furthermore, studies included in our meta-analysis revealed that even after post-CCRT, the distant metastasis rate remains high ranging from 18.3% to 52.6%. Whether the consolidation or induction chemotherapy is needed deserves further exploration. What\'s more, though post-CCRT could provide survival benefit for esophageal cancer patients, the studies conducted with SEER database indicated that preoperative CCRT (or RT) provides superior survival compared with post-CCRT (or RT)[@B33], [@B34]. A network meta-analysis published online recently also confirmed that preoperative CCRT followed by surgery should be the most effective strategy in improving survival of resectable esophageal cancer [@B35]. So we may need to promote preoperative CCRT to maximize the treatment efficacy for esophageal carcinoma. Finally, the optimal radiation dose, target volume, and the most suitable concurrent chemotherapy regimen were not involved in our study. The future trials should be aimed to identify the optimum regimen of post-CCRT.

Conclusions
===========

In conclusion, this meta-analysis including the largest-scale of relatively high quality trials confirms the value of post-CCRT in the treatment of esophageal carcinoma, especially in SCC. Post-CCRT brings about significant survival benefit and improves local-regional control without increased risk of severe toxicities compared with non-CCRT treatment. CCRT merits consideration as a preferred treatment for patients with esophageal carcinoma after surgery. Prospective large scale phase III randomized clinical trial is warranted in the future.
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![**Forest plots of odds ratio (OR) of overall survival in comparison of postoperative CCRT arm to NCCRT arm. (A**) 1-year overall survival; Publication bias: Begg\'s test, P = 0.118; Egger\'s test, P = 0.048. **(B)** 3-year overall survival; Publication bias: Begg\'s test, P = 0.858; Egger\'s test, P = 0.239. **(C)** 5-year overall survival; Publication bias: Begg\'s test, P = 0.020; Egger\'s test, P = 0.014. CI: confidence interval; CCRT: concurrent chemoradiotherapy; NCCRT: non-concurrent chemoradiotherapy](jcav09p0584g002){#F2}

![**Forest plots of odds ratio (OR) of overall survival in comparison of S+CCRT arm to S arm. (A)** 1-year overall survival; **(B)** 3-year overall survival; **(C)** 5-year overall survival. CI: confidence interval; S+CCRT: surgery plus concurrent chemoradiotherapy; S: surgery alone](jcav09p0584g003){#F3}

![**Forest plot of odds ratio (OR) of 5-year overall survival in comparison of S+CCRT arm to S+RT arm.** CI: confidence interval; S+CCRT: surgery plus concurrent chemoradiotherapy; S+RT: surgery plus radiotherapy](jcav09p0584g004){#F4}

![**Forest plots of odds ratio (OR) of recurrence in comparison of postoperative CCRT arm to NCCRT arm. (A)** local-regional recurrence; Publication bias: Begg\'s test, P=0.583; Egger\'s test, P=0.998. **(B)** distant metastasis; Publication bias: Begg\'s test, P=0.189; Egger\'s test, P=0.753. CI: confidence interval; CCRT: concurrent chemoradiotherapy; NCCRT: non-concurrent chemoradiotherapy](jcav09p0584g005){#F5}

###### 

Characteristics of all clinical trials included in the meta-analysis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Researcher and year    Country   Study type   Inclusion criterion             Histology    Radiotherapy                                         Chemotherapy                                                                                   Treatment regimen   Patients number   Time after surgery
  ---------------------- --------- ------------ ------------------------------- ------------ ---------------------------------------------------- ---------------------------------------------------------------------------------------------- ------------------- ----------------- --------------------
  Saito 1993[@B22]       Japan     PHCS         Thoracic ESC;\                  SCC          40-50Gy\                                             CDDP 50mg/m^2^ D21\                                                                            S+CCRT\             35\               1 month
                                                Ⅱ-Ⅳ                                          1.8-2.0Gy per day\                                   VDS 3mg/m^2^ D21\                                                                              S+RT                26                
                                                                                             5 days per week                                      PLM 5mg D22-D26\                                                                                                                     
                                                                                                                                                  Two cycles, interval of 4 weeks                                                                                                      

  Mukaida1998[@B20]      Japan     RCS          ESC                             SCC and AC   40-70Gy\                                             CDDP 50mg/m^2^ D1,D7\                                                                          S+CCRT\             19\               3-4 weeks
                                                                                             1.8-2.0Gy per day\                                   5-FU 500mg/m^2^ D3,D4,D5\                                                                      S+RT\               19\               
                                                                                             5 days per week                                      VP-16 60mg/ m^2^ D3,D4,D5\                                                                     S                   19                
                                                                                                                                                  Two cycles, interval of 4 weeks                                                                                                      

  Bédard2001[@B11]       Canada    RCS          Thoracic ESC & EGJ cancer;\     SCC and AC   50Gy\                                                CDDP 60mg/m^2^ D1\                                                                             S+CT+CCRT\          38\               NA
                                                T1-4,N1,M0                                   2.0Gy per day\                                       5-FU 200mg/m^2^ D1-D21\                                                                        S                   28                
                                                                                             5 days per week                                      ±EPI 50mg/m^2^ D1-D21\                                                                                                               
                                                                                                                                                  First two cycles prior to radiation, then two concurrent with radiation, interval of 3 weeks                                         

  Rice2003[@B21]         USA       RCS          ESC;\                           SCC and AC   50.4-59.4Gy\                                         CDDP 20mg/m^2^ D1-D4\                                                                          S+CCRT\             31\               3-10 weeks
                                                T3-4,N1,M1a                                  1.8Gy per day\                                       5-FU 1000mg/m^2^ D1-D4\                                                                        S                   52                
                                                                                             5days per week                                       Two cycles, interval of 3 weeks                                                                                                      

  Tachibana 2003[@B23]   Japan     RCT          Thoracic ESC;\                  SCC          45-50Gy\                                             CDDP 50mg/m^2^ D1,D5\                                                                          S+CCRT\             22\               Within 2 months
                                                R0 resection                                 2.0Gy per day\                                       5-FU 300mg/m^2^ D1-D35                                                                         S+ CT               23                
                                                                                             5 days per week                                                                                                                                                                           

  Liu2005\               China     PNRCS        Thoracic ESC;\                  SCC          55-60Gy\                                             Concurrent: CDDP 30mg/m^2^ D1 for 6 weeks\                                                     S+CCRT+CT\          30\               2-3 weeks
  [@B18]                                        T3-4,N0-1,M0                                 1.8Gy per day\                                       After completion of radiotherapy:\                                                             S+RT                30                
                                                                                             5days per week                                       CDDP 20mg/m^2^ D1-D5\                                                                                                                
                                                                                                                                                  5-FU 1000mg/m^2^ D1-D5\                                                                                                              
                                                                                                                                                  4 cycles, interval of 1 month                                                                                                        

  Lv2010[@B19]           China     RCT          Thoracic ESC;\                  SCC          Preoperative group:40Gy Postoperative group :50Gy\   CDDP 20mg/m^2^ D1-D3\                                                                          CCRT+S\             80\               4-6 weeks
                                                Ⅱ-Ⅲ                                          2.0Gy per day\                                       TAX 135mg/m^2^ D1\                                                                             S+CCRT\             78\               
                                                                                             5 days per week                                      2 cycles, interval of 3 weeks                                                                  S                   80                

  Cao 2010[@B12]         China     RCT          Thoracic ESC;\                  SCC          50Gy\                                                CDDP 20mg/m^2^ D1-D3\                                                                          S+CCRT\             74\               4-6 weeks
                                                Ⅱ-Ⅲ                                          2.0Gy per day\                                       TAX 135mg/m^2^ D1\                                                                             S                   77                
                                                                                             5 days per week                                      2 cycles, interval of 3 weeks                                                                                                        

  Chen 2011[@B13],\      China     RCS          Thoracic ESC;\                  SCC          50Gy\                                                CDDP 80mg/m^2^ D1-D3\                                                                          S+CCRT\             164\              3-4 weeks
  2013[@B14]                                    N1,M0                                        2.0Gy per day\                                       TAX 135mg/m^2^ D1\                                                                             S+RT                140               
                                                                                             5 days per week                                      1-4 cycles, interval of 3 weeks                                                                                                      

  Wang2014[@B24]         China     RCS          ESC;\                           SCC          45-54Gy\                                             CDDP 25mg/m^2^ D1-D3\                                                                          S+CCRT\             43\               3-6 weeks
                                                R0 resection;\                               1.8-2.0Gy per day\                                   5-FU 1000mg/m^2^ D1-D4\                                                                        S                   47                
                                                ECE in metastatic lymph nodes                5 days per week                                      2 cycles, interval of 4 weeks                                                                                                        

  Hsu2014[@B16]          China     RCS          ESC                             SCC          45-50.4Gy\                                           CDDP 80mg/m^2^ D1\                                                                             S+CCRT\             104\              NA
                                                                                             1.8-2.0Gy per day\                                   5-FU 600mg/m^2^ D1-D4\                                                                         S                   186               
                                                                                             5 days per week                                      LV 90mg/m^2^ D1-D4\                                                                                                                  
                                                                                                                                                  2 cycles                                                                                                                             

  Hwang 2016[@B17]       China     RCS          ESC                             SCC          NA                                                   NA                                                                                             S+CCRT\             147\              6 weeks
                                                                                                                                                                                                                                                 S                   147               

  Hsu 2017[@B15]         China     RCS          ESC;\                           SCC          NA                                                   NA                                                                                             S+CCRT\             213\              6 weeks
                                                R0 resection                                                                                                                                                                                     S                   213               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: PHCS: prospective historical controlled study; ESC: esophageal carcinoma; SCC: squamous cell carcinoma; CDDP: cisplatin; VDS: vindesine; PLM: pepleomycin; S: surgery; CCRT: concurrent chemoradiotherapy; RT: radiotherapy; RCS: retrospective controlled study; AC: adenocarcinoma; 5-FU:5-fluorouracil; VP-16: etoposide; EPI: epirubicin; CT: chemotherapy; NA: not recorded or available; RCT: randomized controlled trial; PNRCS: prospective nonrandomized controlled study; TAX: paclitaxel; ECE: extracapsular extention; LV: leucovorin.

###### 

Meta-analysis outcomes of postoperative CCRT versus non-CCRT for included studies except two in which consolidation chemotherapy were performed.

  Outcomes          Included studies   Sample size   Analysis model   Test for overall effect   I^2^ value for heterogeneity   P value for Begg\'s   P value for Egger\'s           
  ----------------- ------------------ ------------- ---------------- ------------------------- ------------------------------ --------------------- ---------------------- ------- -------
  1-year survival   7                  669           858              F                         1.61 (1.26-2.07)               0.0002                0%                     0.009   0.002
  3-year survival   7                  802           946              F                         1.38 (1.13-1.68)               0.0020                0%                     0.386   0.222
  5-year survival   8                  648           724              F                         1.41 (1.11-1.78)               0.0040                0%                     0.107   0.080

Abbreviations: CCRT: concurrent chemoradiotherapy; NCCRT: non-concurrent chemoradiotherapy; F: fixed-effects model; OR: odds ratio; CI: confidence interval.

###### 

Meta-analysis outcomes of postoperative CCRT versus non-CCRT for SCC

  Outcomes          Included studies   Sample size   Analysis model   Test for overall effect   I^2^ value for heterogeneity   P value for Begg\'s   P value for Egger\'s           
  ----------------- ------------------ ------------- ---------------- ------------------------- ------------------------------ --------------------- ---------------------- ------- -------
  1-year survival   6                  638           806              F                         1.63 (1.26,2.11)               0.0002                0%                     0.007   0.005
  3-year survival   8                  832           976              F                         1.44 (1.18,1.74)               0.0003                3%                     0.917   0.675
  5-year survival   7                  629           686              F                         1.40 (1.10,1.78)               0.0060                0%                     0.174   0.074

Abbreviations: CCRT: concurrent chemoradiotherapy; NCCRT: non-concurrent chemoradiotherapy, F: fixed-effects model, OR: odds ratio, CI: confidence interval.
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